Original article
Statusanalyse und Verbesserungsvorschläge zum Innovationsfonds
02.02.2023
Die siebzehn wichtigsten Fragen an die Versorgungsforschung, gestellt von Franz Knieps, Vorstand des BKK Dachverband, und Prof. Dr. Wolfram Herrmann, Plattform – Charité Versorgungsforschung, Institut für Allgemeinmedizin.
02.02.2023
Persistence problems in patients with rheumatoid arthritis: How can patient support programs (PSP) help?
The authors analyze the problem of low persistence in patients with rheumatoid arthritis and discuss the principles and potential benefits of patient support programs.
26.01.2023
Under the motto “Diabetes care by 2030 – how much progress do we dare?” Novo Nordisk Pharma presented its health policy event series “Diabetes 2030”, which has been taking place at the Royal Danish Embassy in Berlin for six years now. Pia Vornholt, Vice President Public Affairs of the Danish pharmaceutical company, welcomed the numerous participants – including doctors, representatives of health insurance companies and science, as well as patients – with the words: “We are facing major challenges that are innovative require solutions that can only be mastered together". This is exactly where “Diabetes 2030” comes into play as a platform for dialogue, with the stated aim of “discussing concrete recommendations for action” and, starting from diabetes, expanding the focus to other diseases associated with this disease.
30.11.2022
“How can it actually be that we have one of the most advanced and also one of the most expensive healthcare systems in the world, and that despite excellent universities and non-university institutions it is so difficult to bring innovation into care?” With this question, Prof. Dr. med. Peter Falkai, Clinic for Psychiatry and Psychotherapy at the Ludwig Maximilian University of Munich and Congress President of the 21st DKVF, at the press conference in advance of the 21st German Congress for Health Services Research.
30.11.2022
It is a purely diligent task to approach the question of how many of the health care research projects funded by the Innovation Fund and now terminated by a decision by the Innovation Committee were given “positive” or “negative” results, since the G-BA only offers PDF collections. The result speaks for itself, but depends on the interpretation. Some will say: At least 60% received a positive decision if you take into account the projects that received “no recommendation” but for which the results were at least forwarded. The others will notice the number of negative health care research projects: at least 38%.
30.11.2022
“The statutory health insurance system is fundamentally dependent on health services research,” explains Klaus Holetschek, State Minister in the Bavarian State Ministry of Health and Care, in an interview with “Monitor Health Services Research”. It is an important component for updating the GKV service catalog and - according to Holetschek - "of course it is important that the developed forms of care are also implemented in the near future". For this work to be done by health services research, data is essential and concrete requirements for a future health data use law must be specified. The Bavarian Minister of Health: “In my opinion, it is now important that the much-discussed Health Data Usage Act in Germany is introduced as quickly as possible.”
30.11.2022
In nur fünf Jahren will CompuGroup Medical (CGM) vom Software-Unternehmen zu einem bekannten Daten-Player, aber auch Enabler und Katalysator im Ökosystem Gesundheit werden, der für eine bessere Nutzung von Daten im Gesundheitssektor steht. Das erklärt Dr. Eckart Pech, Geschäftsführender Direktor Consumer and Health Management Information Systems von CGM, im Titelinterview mit „Monitor Versorgungsforschung“. Anlass des Gesprächs war die Übernahme des Datenanalysten INSIGHT Health, die dazu führen soll, zu „ganz neuen datengetriebenen Erkenntnissen“ zu kommen. Dies ist keine Zukunftsmusik, sondern mit dem ersten Produkt namens „Darwin Next Generation“ teilweise bereits Realität geworden, indem der INSIGHT Health-Datenpool historisierter Daten mit aktuellen Versorgungsdaten kombiniert wird.
30.11.2022
“How individual data donation can be conveyed as a contribution to medical progress” was the subtitle of the online talk format “Health Loft – Talk of Pioneers” organized by Pfizer. What can successful communication of data donation look like? What specific measures are needed to increase motivation to donate data? And what other hurdles need to be overcome to pave the way for the donation of health data? These and similar questions were examined and discussed in the online talk by experts from different perspectives.
29.11.2022
According to the National Care Guideline (NVL) for the treatment of T2DM, the use of various antidiabetic therapies should be gradual if patients are unable to achieve their individual therapy goals through lifestyle changes, e.g. B. by changing your eating habits and increasing physical activity.3 Known risk factors such as previous cardiovascular and renal diseases should also be taken into account when making individual treatment decisions. The combination of metformin with an SGLT-2 inhibitor (SGLT-2i) or a GLP-1 receptor agonist (GLP-1-RA) is recommended, for example, for patients who already have clinically relevant cardiovascular disease (CVD ).4 Furthermore, dipeptidyl peptidase-4 inhibitors (DPP-4i) in addition to metformin represent another treatment alternative for lowering blood sugar, but did not show significant benefits in reducing cardiovascular events. Cardiovascular diseases cause the highest expenditure in the German healthcare system and are responsible for up to 50% of the treatment costs of patients with T2DM due to the frequently required hospital stays.5 The present healthcare research study compares the direct healthcare costs of T2DM patients who receive treatment with the SGLT -2 inhibitor empagliflozin (EMPA) started with patients treated for the first time with DPP-4i or GLP-1-RA from the perspective of the statutory health insurance in Germany.